Pediatric and Adolescent Unit, Department of Internal Medicine, University of Pavia, Pavia, Italy.
Pediatric Endocrinology Unit, Department of Maternal and Children's Health, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
J Pediatr Endocrinol Metab. 2020 Jul 28;33(7):885-891. doi: 10.1515/jpem-2020-0119.
Objectives Limited data on the evolution of thyroid disorders (TD) in Down syndrome (DS) are available. We characterized the timing, prevalence, and dynamics of TD in patients with DS during a long-term follow-up. Methods We retrospectively evaluated 91 children and adolescents with DS (12.5 ± 8.3; follow-up 7.5 ± 6.2). Children were monitored at birth, 6, and 12 months of age and twice a year thereafter. Thyroid status and autoimmunity were periodically investigated. Results TD were detected in 73.6% of patients, in particular congenital hypothyroidism (CH), autoimmune thyroid diseases (ATD) and subclinical hypothyroidism (SH) were recorded in 16.4, 31.8, and 25.3%, respectively. CH was diagnosed at newborn screening in 86.7% of cases and in the first 6 months of life in the remaining 13.3%; the condition was persistent in 61.5% of patients. In more than 30% of CH cases, glandular hypoplasia was also revealed. In the ATD group, 63.1% of patients with Hashimoto's disease (HD, 82.6%) were treated with levothyroxine and subjects with Graves' Disease (GD, 17.4%) started therapy with methimazole. DS with SH were treated in 42.1% of cases. A thyroid hypogenic echopattern, without autoantibody positivity was identified in 27.6% of SH patients. Conclusions The high prevalence and evolution of TD in SD requires frequent monitoring starting in the first months of life. CH can be misdiagnosed at screening. In DS subjects, there is a high prevalence of ATD and non-autoimmune diseases with early antibody-negative phases should not be excluded.
有关唐氏综合征(DS)患者甲状腺疾病(TD)演变的数据有限。我们对长期随访期间患者的 TD 发病时间、患病率和动态变化进行了特征描述。
我们回顾性评估了 91 名患有 DS 的儿童和青少年(12.5±8.3;随访 7.5±6.2)。在出生、6 个月和 12 个月以及此后每年监测两次。定期检查甲状腺功能和自身免疫情况。
73.6%的患者存在 TD,特别是先天性甲状腺功能减退症(CH)、自身免疫性甲状腺疾病(ATD)和亚临床甲状腺功能减退症(SH)的患病率分别为 16.4%、31.8%和 25.3%。86.7%的病例在新生儿筛查时诊断出 CH,13.3%的病例在生命的前 6 个月诊断出 CH;61.5%的患者持续存在 CH。在超过 30%的 CH 病例中,还发现了腺体发育不良。在 ATD 组中,63.1%的桥本甲状腺炎(HD)患者(82.6%)接受了左甲状腺素治疗,17.4%的格雷夫斯病(GD)患者开始接受甲巯咪唑治疗。42.1%的 SH 患者接受了治疗。27.6%的 SH 患者甲状腺低回声模式,且无自身抗体阳性。
SD 患者 TD 的高患病率和演变需要从生命的头几个月开始进行频繁监测。筛查时可能会误诊 CH。在 DS 患者中,ATD 和非自身免疫性疾病的患病率较高,不应排除早期抗体阴性的情况。